Please login to the form below

Not currently logged in
Email:
Password:

AMNOG – One Year On...

A review of the impact of new pricing and reimbursement arrangements in Germany

Once the first country in Europe to get innovative products thanks to its favourable pricing structure, Germany was a popular launch destination. But the introduction of AMNOG and the G-BA test has left many wondering if they would not be better off avoiding the country altogether Justus Dehnen, Head of Pricing & Reimbursement, IMS Consulting Group and Olaf Zweig, Principal, Booz & Co review the first year of the new arrangements in detail and provide their insights on the likely impact on pharma companies.


The expert panel includes

  • Justus Dehnen, Pricing and Market Access Leader, Germany
  • Olaf Zweig, Principal, Global Health Practice, Berlin

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
DDB Remedy

Sixty years ago Bill Bernbach, Ned Doyle and Maxwell Dane gave the advertising industry a wake-up call.They introduced a new...

Latest intelligence

Children, the weight issue and how we deal with this responsibly?
Say Communication, Healthcare PR Agency, looks at how children deal with the weight issue and how we can approach it responsibly....
Longevity but at what price?
Say Communications, healthcare PR agency, analyses the prospect of living to 150 years old, thanks to the anti-ageing biomedical research, and what PR will look like....
Competition from within
Published in eyeforpharma July 29 by Rachel Howard...

Infographics